Race Oncology Beheer

Beheer criteriumcontroles 1/4

De CEO Race Oncology is Daniel Tillett, benoemd in Nov2023, heeft een ambtstermijn van minder dan een jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 1.12M, bestaande uit 13% salaris en 87% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 10.13% van de aandelen van het bedrijf, ter waarde A$ 25.04M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.9 jaar en 2 jaar.

Belangrijke informatie

Daniel Tillett

Algemeen directeur

AU$1.1m

Totale compensatie

Percentage CEO-salaris	13.0%
Dienstverband CEO	less than a year
Eigendom CEO	10.1%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	2yrs

Recente managementupdates

Recent updates

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 05

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Jun 20

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Feb 17

Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 14

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Apr 01

We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely

Apr 05

What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?

Mar 01

How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table?

Jan 07

Analyse CEO-vergoeding

Hoe is Daniel Tillett's beloning veranderd ten opzichte van Race Oncology's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$1m	AU$145k	-AU$14m
Mar 31 2024	n/a	n/a	-AU$12m
Dec 31 2023	n/a	n/a	-AU$11m
Sep 30 2023	n/a	n/a	-AU$11m
Jun 30 2023	AU$836k	AU$332k	-AU$10m
Mar 31 2023	n/a	n/a	-AU$10m
Dec 31 2022	n/a	n/a	-AU$11m
Sep 30 2022	n/a	n/a	-AU$11m
Jun 30 2022	AU$1m	AU$228k	-AU$11m
Mar 31 2022	n/a	n/a	-AU$10m
Dec 31 2021	n/a	n/a	-AU$9m
Sep 30 2021	n/a	n/a	-AU$8m
Jun 30 2021	AU$1m	AU$167k	-AU$6m
Mar 31 2021	n/a	n/a	-AU$5m
Dec 31 2020	n/a	n/a	-AU$4m
Sep 30 2020	n/a	n/a	-AU$4m
Jun 30 2020	AU$147k	n/a	-AU$4m

Compensatie versus markt: De totale vergoeding ($USD 726.64K ) Daniel } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 706.54K ).

Compensatie versus inkomsten: De vergoeding van Daniel is gestegen terwijl het bedrijf verliesgevend is.

CEO

Daniel Tillett

less than a year

Tenure

AU$1,118,157

Compensatie

Dr. Daniel Tillett is Non-Executive Director of Tryptamine Therapeutics Limited from November 8, 2024. Dr. Tillett joined the Tryptamine Therapeutics Limited on November 8, 2024. Dr. Tillett has been Chief...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Peter Smith	Executive Chairman	1.4yrs	AU$327.72k	geen gegevens
Daniel Tillett	CEO, Managing Director & Director	less than a year	AU$1.12m	10.13% A$ 25.0m
Michelle Rashford	Chief Medical Officer	1.3yrs	AU$704.81k	geen gegevens
Brendan Brown	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Sophia Moscovis	Vice President of Operations & Strategy	less than a year	geen gegevens	geen gegevens
Peter Webse	Company Secretary	8.5yrs	geen gegevens	geen gegevens

0.9yrs

Gemiddelde duur

Ervaren management: Het managementteam van RAC wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.9 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Peter Smith	Executive Chairman	1.4yrs	AU$327.72k	geen gegevens
Daniel Tillett	CEO, Managing Director & Director	less than a year	AU$1.12m	10.13% A$ 25.0m
Martin Tallman	Member of Scientific Advisory Board	7.9yrs	geen gegevens	geen gegevens
Douglas Smith	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Roland Walter	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Borje Andersson	Chairman of Clinical Advisory Board	4.9yrs	AU$815.36k	geen gegevens
Jaap-Jan Boelens	Member of Clinical Advisory Board	4.8yrs	geen gegevens	geen gegevens
Jianjun Chen	Member of Scientific Advisory Board	3.6yrs	geen gegevens	geen gegevens
James Breitenbucher	Member of Scientific Advisory Board	2.5yrs	geen gegevens	geen gegevens
Daniel Hoff	Clinical Advisory Board	less than a year	geen gegevens	geen gegevens
Erin Howden	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Serge Scrofani	Independent Non-Executive Director	less than a year	geen gegevens	geen gegevens

2.0yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van RAC wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2 jaar), wat duidt op een nieuw bestuur.

Race Oncology Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Race Oncology Limited, Annual General Meeting, Nov 25, 2024

Race Oncology Limited Appoints Daniel Tillett as Chief Executive Officer

Race Oncology Limited, Annual General Meeting, Nov 27, 2023

Race Oncology Limited Announces Board Changes

Race Oncology Limited Announces Board Changes

Race Oncology Limited Appoints Michelle Rashford Chief Medical Officer, Effective 1 July 2023

Recent updates

Race Oncology Limited, Annual General Meeting, Nov 25, 2024

Consensus revenue estimates increase by 12%

Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?

Price target increased by 26% to AU$3.22

New minor risk - Share price stability

New minor risk - Shareholder dilution

We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

New minor risk - Shareholder dilution

New major risk - Financial position

We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Race Oncology Limited Appoints Daniel Tillett as Chief Executive Officer

Race Oncology Limited, Annual General Meeting, Nov 27, 2023

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

New minor risk - Share price stability

New minor risk - Financial data availability

Race Oncology Limited Announces Board Changes

New minor risk - Market cap size

Race Oncology Limited Announces Board Changes

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Race Oncology Limited Appoints Michelle Rashford Chief Medical Officer, Effective 1 July 2023

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Race Oncology Limited Appoints Damian Clarke-Bruce as Director

Race Oncology Limited Receives Human Ethics Approval for Observational Cardioprotection Breast Cancer Trial

Race Oncology Limited, Annual General Meeting, Feb 21, 2023

Board Member recently bought AU$50k worth of stock

Board Member recently bought AU$99k worth of stock

Race Oncology Limited Appoints Damian Clarke-Bruce as Managing Director, Effective 1 February 2023

Race Oncology Limited Announces It Has Submitted A Human Ethics Application to Hunter New England Human Research Ethics Committee Seeking Approval to Commence the Observational Stage of A Planned Phase 1/2B Clinical Trial of Zantrene

Race Oncology Limited Appoints Daniel (Danny) Sharp as an Independent Non-Executive Director

Race Oncology Limited Receives Positive Guidance on Zantrene Via Pre-IND Meeting with US FDA

High number of new and inexperienced directors

Race Oncology Ltd Announces Management Changes

Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Race Oncology Limited, Annual General Meeting, Nov 24, 2022

Race Oncology Limited Develops Improved Iv Formulation of Zantrene

Race Oncology Limited Initiates New Drug Discovery Program

Board Member recently bought AU$165k worth of stock

Race Oncology Limited Shares Further Interim Results from Preclinical Cardioprotection Program in Collaboration with Researchers from the University of Newcastle

Race Oncology Limited Announces Interim Results from its Preclinical Melanoma Research Program

Race Oncology Limited Expands FTO Targeting Phase 1b/2a Extramedullary AML & MDS Trial to Europe

Race Oncology Limited Announces the Dose Escalation Phase 1b Stage of the Relapsed or Refractory Acute Myeloid Leukaemia (R/R AML) Trial Running At the Chaim Sheba Medical Centre, Israel

Race Oncology Limited Appoints Guy Breitenbucher to Its Scientific Advisory Board

Race Oncology Limited Receives Governance Approval for AML EMD & MDS Trial

High number of new and inexperienced directors

Race Oncology Limited Receives Human Ethics Approval for Its Open Label Clinical Trial of Zantrene in Patients with Extramedullary Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Race Oncology Limited Announces Preclinical & Clinical Programs Update

Board Member recently bought AU$56k worth of stock

Race Oncology Limited Announces MD Anderson Cancer Center Collaborators Publish Peer Reviewed AML Preclinical Study on Zantrene

Race Oncology Limited Appoints Christina Manfre as Chief Financial Officer

Non-Independent Non-Executive Chairman recently sold AU$995k worth of stock

Board Member recently bought AU$59k worth of stock

Insider recently sold AU$4.4m worth of stock

Race Oncology Limited Announces Interim Results from the Zantrene® Preclinical Heart Safety Research Program Led by Eminent Cardiotoxicity Researchers, Associate Professors Aaron Sverdlov and Doan Ngo

Non-Independent Non-Executive Chairman exercised options to buy AU$9.8m worth of stock.

Non-Independent Non-Executive Chairman recently bought AU$710k worth of stock

Non-Executive Chairman recently sold AU$193k worth of stock

Non-Executive Chairman exercised options to buy AU$5.7m worth of stock.

Insider recently sold AU$4.3m worth of stock

Race Oncology Limited Executes Contract to Commence Phase 1b/2 AML Trial at Chaim Sheba Israel

Insider recently sold AU$4.8m worth of stock

We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely

Insider recently sold AU$6.6m worth of stock

Race Oncology Limited Announces Compelling Preclinical Breast Cancer Results

Insider recently sold AU$2.1m worth of stock

What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?

New 90-day high: AU$3.29

Race Oncology Limited Announces Positive Early Preclinical Ovarian Cancer Results

Professor Borje Andersson to Resign as Chief Medical Officer of Race Oncology Limited